Aim Immunotech INC

AIM ImmunoTech CEO Thomas K. Equels published an article in Breaking Defense discussing the potential of Ampligen as a broad-spectrum antiviral for biodefense applications, including Ebola and coronaviruses.

AIM ImmunoTech reported second quarter 2026 financial results, noting increased cash reserves and reduced R&D expenses, while advancing its Ampligen pancreatic cancer Phase 2 trial towards Phase 3 development.

AIM ImmunoTech has entered into a proposal agreement with Sterling Pharma Solutions for the manufacturing of drug substances to support ongoing and future clinical trials.

AIM ImmunoTech Inc. has mutually terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026, ceasing its at-the-market offering program.

AIM ImmunoTech Inc. held a Special Meeting of Stockholders on July 15, 2026, where shareholders approved several proposals related to stock issuance and a potential reverse stock split.

AIM ImmunoTech has regained compliance with NYSE American continued listing standards, resolving stockholder equity deficiencies through recent capital raises.

AIM ImmunoTech's Q2 2026 report shows substantial cash infusion from financing activities and regained NYSE American compliance, while R&D spending decreases.

AIM ImmunoTech reported reduced net losses for Q3 and the first nine months of 2025, driven by cost-cutting and a legal fee settlement, despite declining revenue and ongoing liquidity concerns.

AIM ImmunoTech reported increased net losses for the quarter, significant cash depletion, and a going concern warning, despite regaining NYSE American listing after a reverse stock split and securing new financing.

AIM ImmunoTech reports a decreased net loss for Q1 2025 but faces challenges including a potential delisting from NYSE American and going concern uncertainties.

AIM ImmunoTech's Q3 2024 results show a reduced net loss compared to the previous year, alongside ongoing clinical trial advancements and strategic financial maneuvers.

AIM ImmunoTech reported a reduced net loss for Q2 2024 compared to Q2 2023, alongside updates on clinical trials and financial activities.

AIM ImmunoTech's 2025 annual report highlights a strategic pivot to late-stage pancreatic cancer for Ampligen, despite ongoing financial losses and NYSE American delisting concerns.

AIM ImmunoTech reports a reduced net loss for 2024 but faces substantial doubt about its ability to continue as a going concern and potential delisting from the NYSE American due to stockholders' equity deficiency.

AIM ImmunoTech's 10-K filing outlines the characteristics of its common stock, including voting, dividend, and liquidation rights, as well as anti-takeover provisions.

AIM ImmunoTech's CEO, Thomas K. Equels, converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock.

AIM ImmunoTech Director David I. Chemerow converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock.

AIM ImmunoTech Inc. Director David I. Chemerow has filed a Form 4 indicating a planned acquisition of 2,800 common shares on February 5, 2026, through a trust.

AIM ImmunoTech Director and 10% Owner Ted D. Kellner has filed a Form 4 disclosing a planned transfer of his directly held shares to Kelvest I LP, effective July 17, 2025, under a Rule 10b5-1 plan.

AIM ImmunoTech Inc.'s CEO and President, Thomas K. Equels, acquired 107 shares of common stock at $7.697 per share, increasing his direct beneficial ownership to 38,885 shares.

AIM ImmunoTech Inc.'s CEO and President, Thomas K Equels, has reported the direct acquisition of 103 shares of common stock at a price of $8.70 per share, increasing his total direct beneficial ownership to 38,675 shares.

AIM ImmunoTech is seeking shareholder approval for multiple warrant issuances and a potential reverse stock split to maintain NYSE American listing compliance.

AIM ImmunoTech Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 16, 2025, focusing on director elections, auditor ratification, and executive compensation votes.

AIM ImmunoTech is asking stockholders to approve a reverse stock split of up to 1-for-100 to increase its stock price, maintain its NYSE American listing, and improve marketability.

AIM ImmunoTech has distributed additional materials to stockholders regarding the 2024 Annual Meeting, emphasizing the importance of reviewing the definitive proxy statement and related documents.

AIM ImmunoTech is urging shareholders to vote for the current board members at the upcoming annual meeting, warning against the potential risks posed by an activist investor group.

AIM ImmunoTech is urging shareholders to vote for the current board members, highlighting concerns about an activist group's motives and lack of a clear plan.

AIM ImmunoTech Inc. has filed an S-1 registration statement to allow for the resale of up to 13,077,089 shares of common stock by selling stockholders.

AIM ImmunoTech Inc. has filed an S-1 registration statement to allow for the resale of up to 31,287,933 shares of common stock by selling stockholders.

AIM ImmunoTech Inc. files an S-1/A for a rights offering to raise capital through the distribution of units comprising Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants to existing shareholders and warrant/option holders.

AIM ImmunoTech Inc. is conducting a non-transferable rights offering to raise up to $12 million for general corporate purposes, clinical trials, and debt repayment, while facing NYSE American listing non-compliance.

AIM ImmunoTech Inc. announced a non-transferable rights offering to raise up to $12 million through the sale of units comprising Series G Convertible Preferred Stock and warrants, while providing updates on its Ampligen clinical programs.

AIM ImmunoTech Inc. is conducting a non-transferable subscription rights offering to raise up to $12 million by selling units consisting of Series G Convertible Preferred Stock and Warrants.

Reporting persons Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a zero percent beneficial ownership stake in AIM ImmunoTech Inc. as of May 27, 2026.

Armistice Capital, LLC and Steven Boyd have filed an amendment to their Schedule 13G, disclosing a 4.99% passive ownership stake in AIM ImmunoTech Inc. as of December 31, 2024.